Seroprotection after hepatitis A vaccination in patients with drug-induced immunosuppression

Journal of Travel Medicine

Volumn 20, Issue 5, 2013, Pages 278-282

  Van Den Bijllaardt, Wouter ^a   Siers, Helen M ^a   Timmerman Kok, Caroline ^b   Pessers, Franciscus G ^a   Natrop, Gerard ^c   Van Baars, Joep F ^d   Nutma, Nynke ^e   Van Der Werf, Douwe ^f   Gisolf, Elizabeth H ^g,h  

^a GGD Gelre IJssel (Community Health Service)   (Netherlands)

^b Public Health Service (GGD) Gelre IJssel   (Netherlands)

^c Public Health Services Gelderland Midden   (Netherlands)

^d Department of Infectious Diseases   (Netherlands)

^e Municipal Health Service GGD Rivierenland   (Netherlands)

^f GGD IJsselland   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h Travel Clinic Oost   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; GENDER; HEPATITIS A; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SEROLOGY; VACCINATION;

ADULT; AGED; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TRAVEL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84883458245     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12050     Document Type: Article

References (28)

1. Van Herck K, Van Damme P,. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005; 4: 459-471.
2. Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP,. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2006; 55: 1-23.
3. Landelijk coördinatiecentrum reizigersadvisering. National Coordination Centre for Travelers' Health Advice. National guidelines for travelers' health advice. Amsterdam: Landelijk coördinatiecentrum reizigersadvisering, 2008.
4. van Steenbergen JE, Timen A,. LCI hepatitis A, May 2009. In:, Beaujean DJMA, ed. LCI-guidelines infectious disease control. 2011 Edition. Bilthoven: LCI, Coordinator Infectious Disease Netherlands, 2011: 218-226.
5. Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171 (Suppl 1): S44-S49.
6. André F, Van Damme P, Safary A, Banatvala J,. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 2002; 1: 9-23.
7. Van Herck K, Van Damme P,. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63: 1-7.
8. Ashur Y, Adler R, Rowe M, Shouval D,. Comparison of immunogenicity of two hepatitis A vaccines-VAQTA and HAVRIX-in young adults. Vaccine 1999; 17: 2290-2296.
9. Nothdurft HD,. Hepatitis A vaccines. Expert Rev Vaccines 2008; 7: 535-545.
10. Gelinck LB, Roukens AHE, Kroon FP, Visser LG,. Praktische adviezen voor reizigers met een afweerstoornis. Ned Tijdschr Geneeskd 2008; 152: 1725-1729.
11. Neilsen GA, Bodsworth NJ, Watts N,. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997; 176: 1064-1067.
12. Launay O, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008; 49: 272-275.
13. Shire NJ, Welge JA, Sherman KE,. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine 2006; 24: 272-279.
14. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75-81.
15. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29: 1643-1648.
16. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011; 118: 6769-6771.
17. Gelinck LB, Teng YK, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007; 66: 1402-1403.
18. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-716.
19. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65: 191-194.
20. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P,. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007; 46: 608-611.
21. Brezinschek HP, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008; 20: 295-299.
22. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, et al. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001; 19: 589-594.
23. Versluis DJ, Beyer WE, Masurel N, et al. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986; 42: 376-379.
24. Health Council of the Netherlands. Variant Creutzfeldt-Jakob disease and blood transfusion. The Hague: Health Council of the Netherlands, 2001; publication no. 2001/02.
25. Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, Lelie PN,. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J Med Virol 1993; 40: 22-27.
26. D'Acremont V, Herzog C, Genton B,. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med 2006; 13: 78-83.
27. De Melker HE, van der Peet TE, Berbers GAM, et al. Seroprevalenties voor bof, mazelen, rubella, kinkhoest, Toxoplasma Gondii, Toxocara, T. spiralis en hepatitis A. Bilthoven, the Netherlands 1995. RIVM Report 213675004.
28. GlaxoSmithKline UK. Havrix Monodose Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/2041/SPC/ Havrix+Monodose+Vaccine. (Accessed 2012 Aug 13)